These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
869 related articles for article (PubMed ID: 21216837)
1. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837 [TBL] [Abstract][Full Text] [Related]
2. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365 [TBL] [Abstract][Full Text] [Related]
3. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Liu H; Liu ZY; Guan Q Interact Cardiovasc Thorac Surg; 2007 Oct; 6(5):608-13. PubMed ID: 17670742 [TBL] [Abstract][Full Text] [Related]
4. Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats. Dai ZK; Tan MS; Chai CY; Chou SH; Lin PC; Yeh JL; Jeng AY; Chang CI; Chen IJ; Wu JR Exp Biol Med (Maywood); 2006 Jun; 231(6):942-7. PubMed ID: 16741028 [TBL] [Abstract][Full Text] [Related]
6. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling. Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256 [TBL] [Abstract][Full Text] [Related]
7. Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent? Kuhn M Cardiovasc Res; 2009 Apr; 82(1):4-6. PubMed ID: 19221131 [No Abstract] [Full Text] [Related]
9. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. Vassalos A; Peng E; Young D; Walker S; Pollock J; Macarthur K; Lyall F; Danton MH Anaesthesia; 2011 Jun; 66(6):472-80. PubMed ID: 21457152 [TBL] [Abstract][Full Text] [Related]
10. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Westermann D; Becher PM; Lindner D; Savvatis K; Xia Y; Fröhlich M; Hoffmann S; Schultheiss HP; Tschöpe C Basic Res Cardiol; 2012 Nov; 107(6):308. PubMed ID: 23117837 [TBL] [Abstract][Full Text] [Related]
11. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Rossoni G; Manfredi B; De Gennaro Colonna V; Berti M; Guazzi M; Berti F Br J Pharmacol; 2007 Mar; 150(5):567-76. PubMed ID: 17245365 [TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. Botha P; Parry G; Dark JH; Macgowan GA J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695 [TBL] [Abstract][Full Text] [Related]
13. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618 [TBL] [Abstract][Full Text] [Related]
14. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats. Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207 [TBL] [Abstract][Full Text] [Related]
15. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Gao S; Long CL; Wang RH; Wang H Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734 [TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat. Jasińska-Stroschein M; Owczarek J; Wesołowska A; Orszulak-Michalak D Acta Pharm; 2014 Sep; 64(3):345-53. PubMed ID: 25296680 [TBL] [Abstract][Full Text] [Related]
17. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636 [TBL] [Abstract][Full Text] [Related]
18. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Jerkic M; Kabir MG; Davies A; Yu LX; McIntyre BA; Husain NW; Enomoto M; Sotov V; Husain M; Henkelman M; Belik J; Letarte M Cardiovasc Res; 2011 Dec; 92(3):375-84. PubMed ID: 21859819 [TBL] [Abstract][Full Text] [Related]
19. Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension. Sirmagul B; Ilgin S; Atli O; Usanmaz SE; Demirel-Yilmaz E Clin Exp Hypertens; 2013; 35(3):220-7. PubMed ID: 22967272 [TBL] [Abstract][Full Text] [Related]
20. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Andersen A; Nielsen JM; Peters CD; Schou UK; Sloth E; Nielsen-Kudsk JE Eur J Heart Fail; 2008 Dec; 10(12):1158-65. PubMed ID: 19004667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]